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Cervical cancer remains an important cause of 
morbidity and mortality in South Africa (SA). A 
national cervical cancer prevention programme 
exists that offers three cervical cytology smears 
per lifetime, starting after the age of 30 at 10-year 
intervals. Despite this programme the incidence remains unacceptably 
high, cases are often diagnosed late, and many patients have poor 
response to treatment. Primary healthcare systems in many areas are 
poorly developed, and uptake of cytological screening is generally 
poor, with some metropolitan areas and regions doing slightly 
better. Health systems interventions are necessary to improve the 
quality of screening.[1] In addition, there is often significant loss to 
follow-up after the initial screening test among women identified 
with abnormal cytology. Determinants of the high cervical cancer 
rate and poor outcome of treatment are similar to those in other 
developing countries and include a low doctor/population ratio, a 
high prevalence of HIV infections, and competing healthcare needs. 
A lack of consumer (patient) knowledge and empowerment leads to 
a low degree of health-seeking behaviour.
Disease prevention
Disease prevention strategies can be broadly categorised as primary 
prevention and secondary prevention. Primary prevention aims to 
reduce the risk of an individual contracting a particular disease by 
eliminating the aetiological agents from the environment. In the case 
of cervical cancer, the most important risk factor for the development 
of premalignant and malignant disease is persistent infection with 
oncogenic types of human papillomavirus (HPV) infection.
Since the approval of the HPV vaccines in SA in 2008, they have 
been available in the private market. Uptake has been slow because 
of factors such as the initial high costs of both vaccines, poor 
community knowledge of cervical cancer and the causal relationship 
between HPV and cervical cancer, and lack of population experience 
with and acceptance of vaccines targeting adolescents.[2,3] A school-
based introduction was suggested for SA.[4] The national Department 
of Health introduced an HPV vaccine roll-out programme in April 
2014. Introduction of the HPV vaccination programme in public 
schools is widely supported by scientists and healthcare workers 
involved in the prevention and treatment of cervical cancer, who 
emphasise the excellent efficacy and safety record of the vaccines.[5]
Linking health interventions may achieve cost-effective ways 
of preventing disease. Information from a qualitative study in SA 
concluded that HPV vaccination can be linked to other adolescent 
preventive health services.[6] The strong link between HIV infection 
and immunosuppression with HPV-associated disease is well 
established. By controlling HIV, the incidence of HPV-related disease 
will also be reduced. In addition, HIV treatment facilities can be used 
to monitor cervical screening and treatment.
Smoking is associated with an increased risk of development 
of squamous and other carcinomas of the cervix, and a national 
antismoking campaign, like the programme introduced in SA under 
health minister Dlamini-Zuma, would be highly effective in reducing 
smoking-related diseases including cervical cancer.
Secondary prevention by screening has been shown to reduce 
cervical cancer significantly when comprehensive population-based 
call-and-recall programmes were introduced. Since the SA cervical 
cytology programme is not a programme of this sort and has low 
uptake rates, success has been limited. Opportunistic screening 
will continue to be an important part of our programme for the 
foreseeable future. Linking opportunistic screening of mothers to 
vaccination of their children is a potential way to increase disease 
awareness and screening uptake.
Adolescent vaccination programmes
The successful introduction of a school-based vaccination programme 
is a momentous task, especially in settings like SA where no national 
adolescent, adult or school-based vaccination programmes existed 
before roll-out. Education of healthcare practitioners and the general 
public will be crucial to the success of such a programme, as no 
framework and culture for the immunisation of older youth and adult 
populations are established in SA. HPV vaccine implementation 
programmes from other countries have shown that a school-based 
approach is most successful when HPV vaccines are introduced 
in girls 9 - 14 years of age.[7] The first of a series of three articles 
describing the Vaccine and Cervical Cancer Screen (VACCS) project 
appears in this issue of SAMJ.[8] These pilot projects combined 
vaccination of adolescent girls against HPV with cervical cancer 
screening interventions offered to their female caregivers.
Lessons that can be learned from such vaccination pilot projects 
are useful to guide nationwide implementation locally and in other 
African countries. Barriers that had to be addressed included the 
challenges associated with administration of a three-dose vaccine 
in a busy school calendar. A two-dose schedule was investigated 
in phase 2 of the study in the light of new efficacy data in girls 
9 - 14 years of age.[9] The relative lack of health infrastructure for 
adolescent vaccination programmes was overcome by using school-
based infrastructure and dedicated roving vaccination teams.
Parental or caregiver consent procedures could impact on vaccine 
uptake in school-based programmes and may be a barrier to new 
vaccine introduction.[7] Clear messages to parents will reduce the 
likelihood of negative publicity and address concerns about safety. 
Vaccine uptake among girls whose caregivers attended information 
evenings were significantly better (almost 90%) than that among 
girls whose caregivers did not attend (around 50%),[8] underscoring 
the importance of information dissemination, creating of awareness 
and disease-specific education. Information must be distributed 
using multiple strategies, which can utilise health workers or 
teachers.[7] Providing written information only may not be enough 
in some communities. Overall, only around 50% of all invited girls 
were ultimately sufficiently vaccinated, mainly owing to lack of 
parental consent. After similar experiences, alternative strategies were 
employed in some countries. Community-based consent strategies 
that negated individual parental consent was introduced in Vietnam 
and Uganda, and parent opt-out strategies were used in Tanzania 
and Rwanda.[7] The acceptability of mandatory vaccination in the SA 
context will probably be problematic.
Vaccine course completion rates were addressed. A limitation 
of the national HPV vaccine roll-out programme is the absence of 
alternative vaccination opportunities when vaccination is missed 
as a result of absenteeism. The VACCS trials showed that at 
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least two opportunities may be needed per facility because of 
illness or school-related activities that could cause girls to miss the 
vaccination opportunity, especially if a two-dose schedule is used. 
HPV vaccine coverage and completion rates may also increase 
by the introduction of an additional public health facility-based 
HPV vaccination programme, which currently does not exist. The 
importance of grade-based as opposed to age-based eligibility criteria 
and completion of the vaccination series in one calendar year, as is 
done in the national roll-out, is highlighted by these data.
Linking vaccination and screening
An exciting and novel approach is the linking of cervical cancer 
screening of female caregivers to the vaccination of schoolgirls. Even 
though the uptake of self-screening for high-risk HPV was relatively 
low, a significant proportion (around 30%) of women at increased 
risk for cervical cancer were identified. It is important to understand 
that the aim of home-based cervical cancer screening is as an adjunct 
to existing healthcare facility-based screening programmes to reach 
unscreened, high-risk women who did not access healthcare. An 
additional benefit of linking screening to vaccination is the ease of 
traceability of screened women, which decreases the loss to follow-up 
experienced in the current national screening programme.
Implementation of HPV vaccine programmes and extension of 
cervical cancer screening programmes in African countries are important 
steps towards reducing the high burden of cervical cancer in this region.
Future considerations
Screening with HPV testing will almost certainly replace traditional 
cervical cytology in the not-too-distant future. Studies to evaluate 
the validity of the various HPV tests in our setting are extremely 
important. Higher rates of HPV infection, possible differences in 
genotype distribution and the effects of a high background incidence 
will affect the performance characteristics of HPV-based screening. The 
possibility of patient-collected (self-sampling) specimens will cater for a 
large number of women who may not have access to healthcare facilities.
HPV vaccination will only make a significant impact if high 
enough vaccination rates can be achieved. Continuing education of 
the public and of healthcare workers is essential. Monitoring of the 
programme to evaluate vaccination rates needs to be in place from 
the start. A catch-up school-based vaccination campaign to include 
a larger cohort of girls, perhaps up to 18 years of age, will be cost-
effective and may produce herd protection.
Conclusion
There is currently no comprehensive cervical cancer control 
programme in place. We urgently need to outline strategies to:
• maximise the number of individuals receiving HPV vaccines
• monitor the vaccination programme effectively
• commit to a screening policy, with consideration of HPV testing 
and self-sampling. 
In primary and secondary prevention of cervical cancer, opportunities 
for linkage with existing infrastructure and services should be 
investigated.
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